GlassScriptPhysician profile
Terry Jo Brooks-Devlin
NPI 1831526763
$175,733.28
in general payments reported to CMS, 2019-2025
23 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $32K · 2023: $39K · 2024: $34K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Consulting Fee: $22K · Food and Beverage: $15K · Travel and Lodging: $9,788 · Honoraria: $5,375 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,431.25 |
| Consulting Fee | $21,793.00 |
| Food and Beverage | $14,874.01 |
| Travel and Lodging | $9,787.90 |
| Honoraria | $5,375.00 |
| Education | $158.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $53,963.70 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $40,324.13 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $24,541.35 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $20,476.42 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $18,609.77 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $7,069.37 | 2023-2025 | Auvelity |
| Abbvie INC. | $3,672.98 | 2021-2025 | |
| Indivior INC. | $3,063.24 | 2021-2025 | Perseris, Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,648.94 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $944.50 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $530.89 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $343.49 | 2022-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $118.59 | 2021 | |
| Gilead Sciences, INC. | $90.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.11 | 2022-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $71.64 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $47.17 | 2021-2024 | Secuado, Xelstrym |
| Luye Pharma (USA) LTD. | $38.30 | 2025 | Erzofri Extended-Release |
| Corium, LLC | $32.38 | 2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $28.65 | 2022 | |
| Eisai INC. | $16.91 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.59 | 2025 | Jornay Pm |
| Biogen, INC. | $14.16 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Jo Brooks-Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.